Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2024-01-01
|
| Серии: | Cancer Treatment and Research Communications |
| Предметы: | |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S2468294225000012 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|